Regadenoson is a better myocardial vasodilator than dipyridamole in normal volunteers, but the data is less compelling in patients

  • Vasu S
  • Bandettini W
  • Hsu L
  • et al.
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction : Regadenoson is a selective Adenosine-2A receptor agonist and is used for myocardial perfusion imaging. Dipyridamole causes indirect vasodilation by inhibiting cellular reuptake of adenosine. The purpose of this study was to assess whether regadenoson is a better coronary vasodilator than dipyridamole in normal volunteers and in patients. Hypothesis Regadenoson causes a 25% higher myocardial blood flow (MBF) than dipyridamole. Methods Forty patients with normal coronaries/minimal stenosis on coronary CT angiography had also undergone vasodilator stress MR (regadenoson n=20, dipyridamole n=20). Seventeen healthy normal volunteers with Framingham score less than 1% underwent vasodilator stress testing with regadenoson and dipyridamole in two separate studies using a SSFP sequence. Stress imaging was done 70 seconds post regadenoson injection and 4 minutes after completing the dipyridamole infusion. All patients and volunteers received aminophylline after stress imaging. Rest imaging was done 20 minutes later. MBF in ml/min/g and Myocardial perfusion reserve (MPR) were quantified using a fully quantitative model constrained deconvolution (MCD). Results Normal volunteers had higher stress MBF (mean (plus or minus) standard error) with regadenoson than dipyridamole (3.72(plus or minus) 0.18 vs. 2.90(plus or minus) 0.17, p=0.001) and higher MPR with regadenoson (2.75(plus or minus) 0.19 vs. 2.27(plus or minus)0.14, p=.03). In patients, higher MPR was found with regadenoson (2.45 (plus or minus) 0.12, vs. 2.12 (plus or minus).10, p=.04). Stress MBF trended higher in patients with regadenoson than dipyridamole (2.78(plus or minus) 0.14 vs. 2.54(plus or minus) 0.13, p=0.22). No difference in the resting blood flow between regadenoson and dipyridamole was found in normal volunteers (1.44(plus or minus) 0.19 vs. 1.31(plus or minus)0.07,p=.07) and in patients (1.14(plus or minus)0.03 vs. 1.24(plus or minus)0.08, p=.26) respectively. Figures 1-3. Conclusions Regadenoson is a better coronary vasodilator than Dipyridamole in normal volunteers with higher MBF and MPR. However in patients, the small sample size in this study limits the sensitivity to detect differences in stress perfusion. (Graph Presented).

Cite

CITATION STYLE

APA

Vasu, S., Bandettini, W. P., Hsu, L.-Y., Kellman, P., Chen, M. Y., Wilson, J., … Arai, A. E. (2011). Regadenoson is a better myocardial vasodilator than dipyridamole in normal volunteers, but the data is less compelling in patients. Journal of Cardiovascular Magnetic Resonance, 13(S1). https://doi.org/10.1186/1532-429x-13-s1-p124

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free